Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458588 | 0.80 | TLR8 (0.57) | TLR8TLR7 | |
| SCHEMBL22498767 | 0.79 | TLR8 (0.58) | TLR8TLR7 | |
| SCHEMBL29377718 | 0.79 | TLR8 (0.58) | TLR8TLR7 | |
| SCHEMBL28203089 | 0.79 | TLR8 (0.58) | TLR8TLR7 | |
| SCHEMBL28510573 | 0.73 | TLR8 (0.54) | TLR8TLR7 | |
| SCHEMBL3321246 | 0.72 | PDPK1 (0.52) | TLR8PDPK1TLR7 | |
| SCHEMBL28504818 | 0.72 | TLR8 (0.51) | TLR8TLR7 | |
| SCHEMBL29768670 | 0.71 | LIMK1 (0.51) | ADORA1DHFR | |
| Benzene SCHEMBL28801411 | 0.70 | GPR84 (0.41) | TLR8TLR7ADORA3ADORA2AADORA2B | |
| SCHEMBL1260043 | 0.70 | DHFR (0.59) | ADORA2ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022077-B2 | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-09-20 | — | — | US | disclosed |
| EP-1888580-B1 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARM LTD (IE) | 2010-03-03 | — | — | EP | disclosed |
| US-20090131460-A1 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-05-21 | — | — | US | disclosed |
| EP-1888580-A2 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | Tibotec Pharmaceuticals Ltd. (IE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006120252-A2 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131460-A1 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | DPYD, TYMP, PNP | PDE4A 789/4885PDE4B 698/4885PDE4C 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.